Aurora Cannabis Inc.

NASDAQ:ACB

Drug Manufacturers - Specialty & Generic

Healthcare
$4.40 +0.51%

+$0.02 today

Market cap
$289.28M
Beta
1.34
P/E (TTM)
-3.2
EPS (TTM)
-$1.31
52W Low $2.73High $6.67

Volume 0.92M

Average 1.00M

ACB Debt Repayment

Cash used to repay borrowings during the period.

Aurora Cannabis Inc.NASDAQ: ACB

Debt Repayment · Q4 FY2026 · quarter ended Mar 2026

Debt repayment dips below year-ago levels

Q4 FY2026 debt repayment of CA$37.1K fell 98.4% year over year, behind the +426.3% change in trailing-twelve-month debt repayment. Sequentially, it fell 94.7% from the prior quarter.

Context

  • Debt repayment amounted to 1.6% of revenue in FY2026, up 1.3 pp from a year earlier.
  • Debt repayment grew in size in 1 of the last 2 fiscal years.

What to watch

Whether quarterly growth recovers from -98.4% toward the trailing-twelve-month pace of +426.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$37.1K-94.7% QoQ
Last fiscal yearMar 2026
-CA$5.02M+523.5% YoY
LTMMar 2026
-CA$4.24M+426.3% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-98.4%——
1 year+523.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

CAD · from the cash flow

Latest · FY2026
(5.02M) CAD
Year-over-year change
-523.5%

Debt Repayment vs competitors

How ACB compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +426.3% is the 2nd highest of 8, against a peer median of +93.3%.
  • Debt repayment amounts to 1.4% of revenue for ACB, versus a peer median of 4.1%.
ACB Competitors
Debt Repayment for ACB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LFMDLifeMD, Inc.LTM Mar 2026$18.72M USD+16050.6%—8.5%
HITIHigh Tide Inc.LTM Apr 2026CA$13.58M CAD+180.5%—2.0%
CGCCanopy Growth CorporationLTM Mar 2026CA$13.52M CAD-93.9%—4.3%
BIOABioAge Labs, Inc.LTM Mar 2026$6M USD+0.0%—58.2%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$5.13M USD—-30.6%3.8%
ACBAurora Cannabis Inc.LTM Mar 2026CA$4.24M CAD+426.3%—1.4%
EDITEditas Medicine, Inc.LTM Mar 2026$2.87M USD——7.4%
TKNOAlpha Teknova, Inc.LTM Mar 2026$2.15M USD+93.3%-52.2%5.1%
OGIOrganigram Global Inc.LTM Mar 2026CA$599.78K CAD-46.4%—0.2%
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$0 USD+100.0%—0.0%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding ACB) —+93.3%-41.4%4.1%

Competitors are the stored peer set for ACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2022
Jun 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Net Income(1.72B)(265.33M)(57.08M)15.76M(58.77M)
Depreciation & Amortization93.66M43.57M32.78M22.55M14.23M
Deferred Income Tax(2.19M)(18.4M)(1.67M)(3.19M)55.14K
Stock-Based Compensation13.76M16.89M12.72M11.52M7.29M
Change in Working Capital52.65M(25.12M)(15.54M)10.21M(9.24M)
Accounts Receivables18.34M5.53M(4.5M)5.24M(8.17M)
Inventory21.07M49.03M3.87M(15.05M)65.93M
Accounts Payables6.77M(8.06M)(15.7M)14.91M(8.06M)
Other Working Capital6.48M(71.61M)790K5.11M(58.93M)
Other Non-Cash Items1.45B190.11M(39.71M)(40.85M)40.18M
Operating Cash Flow(110.27M)(115.82M)(68.51M)16.01M(13.55M)
Capital Expenditures(32.21M)(12.13M)(16.83M)(18.86M)(22.6M)
Acquisitions (Net)(23.42M)(18.54M)(5.55M)01.1M
Purchases of Investments0000(52.35M)
Sales of Investments03.36M4.99M5.49M0
Other Investing Activities19.46M16K14.02M(956K)235.61K
Investing Cash Flow(36.17M)(27.29M)(3.36M)(14.33M)(73.62M)
Debt Repayment(170.83M)—(85.37M)(805K)(5.02M)
Common Stock Issued350.19M73.19M37.92M820K9.94M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(31.58M)(95.21M)(475K)(131K)(154.4K)
Financing Cash Flow147.78M(56.48M)(47.92M)(116K)9.79M
Effect of Forex Changes15.01M15.54M297K264K10.56M
Net Change in Cash16.35M(140.01M)(119.5M)1.83M(66.81M)
Free Cash Flow(142.48M)(127.95M)(85.34M)(2.85M)(36.15M)

Aurora Cannabis Inc.

NASDAQ:ACB

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.